ASAndreas Salat

Andreas Salat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andreas Salat has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Full Robotic Kidney Transplantation

    by Andreas Salat, Jakob Eichelter

    Kidney transplantation (KT) has proved excellent results treating of end-stage renal failure regarding survival and quality of life and therefore became the first choice during the last decades. Despite this, standard open kidney transplantation (OKT) might be complicated – among others – by surgical site infections, incisional hernias, and symptomatic lymphoceles, especially in obese patients. That’s why some centers limit their acceptance for OKT to a body mass index below 35 kg/m2. Due to the increasing obesity prevalence worldwide, there is, on one hand, a need to challenge the gold standard to be able to offer obese patients the advantages of KT and, on the other hand, to reduce perioperative complications. During last years, robotic surgery has developed rapidly and meanwhile gained a pole position in urology (e.g., prostatic cancer) as well as in some fields of general surgery (e.g., colorectal cancer). Some years ago, visionary experts started programs on robotic-assisted donor nephrectomy (RADN) as well as robotic-assisted kidney transplantation (RAKT). Data show feasibility, safety, and outstanding perioperative results. Meanwhile, there comparative data on RAKT versus OKT are available, pushing RAKT to the first choice in living donor (LD) kidney transplantation. Single centers also use RAKT for cadaveric organs, however limited due to the acute situation, the reduced availability of robotic devices, and trained surgeons. The aim of this article was to show the present status of RADN and RAKT concerning technique and results, to motivate transplant surgeons to introduce RAKT at their centers, and to reduce concerns regarding costs in economic administration.

  • Donor bone marrow together with recipient regulatory T cells induces chimerism without irradiation in kidney transplantation

    by Thomas Wekerle, Moritz Muckenhuber, Andreas Heinzel, Anna Marianne Weijler, Ana F. David, Verena Kainz, Karin Hu, Jasmin Mucha, Konstantinos Mengrelis, Roman Reindl-Schwaighofer, et al.

    Cotransplantation of donor bone marrow (BM) has yielded a therapeutic benefit in clinical trials of kidney transplantation by inducing chimerism-based tolerance, but this was dependent on unfavorable recipient irradiation. Additional regulatory T (T reg ) cell administration can overcome the need for myelosuppression, but this has been demonstrated only in mice so far. Here, we conducted a controlled, phase 1/2a trial of combined BM and T reg cell therapy in HLA-mismatched living-donor kidney transplantation (NCT03867617). Six patients received polyclonal recipient T reg cells and donor BM cells (BMCs) immediately posttransplant. Immunosuppression consisted of thymoglobulin, belatacept, sirolimus, steroids, and short-course tocilizumab. The control group received no T reg cells, BMCs, or tocilizumab. Total leukocyte donor chimerism was detected across all patients in the study group posttransplantation. This was not observed in any patient belonging to the control group, consequently meeting the primary end point of higher chimerism levels in the study versus control groups ( P = 0.001). Chimerism was observed across multiple lineages, with up to 4% in T cells. For three patients in the study group, immunosuppression could be minimized to belatacept monotherapy. Antidonor reactivity was decreased in in vitro T cell proliferation assays, suggesting specific downmodulation of the antidonor T cell response. In addition, expansion of antidonor T cell clones was shown by T cell receptor sequencing analysis to be dampened in the study versus control groups. This trial serves as a proof of concept for a combination cell therapy that induces chimerism-based immunomodulation in kidney transplantation without the need for irradiation.


  • Open Access

    HTK Is a Viable UW Alternative for Hypothermic Oxygenated Machine Perfusion of Liver Grafts Supporting a Single-Solution Protocol

    by Jule Dingfelder, David Pereyra, Moriz Riha, Nikolaus Becker, Laurin Rauter, Hubert Hackl, Julian Flavio Müller, Felix Hammer-Purgstall-Bernd, Monika Aiad, Jakob Eichelter, et al.

    Background and Aims: Hypothermic oxygenated machine perfusion (HOPE) improves outcomes in orthotopic liver transplantation (OLT), but reliance on University of Wisconsin machine perfusion solution (UW-MPS) increases costs and logistical burden. Histidine-tryptophan-ketoglutarate (HTK) has potential as a single-solution alternative for HOPE. This study evaluated the safety and efficacy of HTK versus UW-MPS during HOPE. Methods: A retrospective, propensity score-matched cohort study including 46 patients who received donation after brain death (DBD) grafts that were preserved with HOPE at the Medical University of Vienna between May 2018 and October 2024 was conducted. A total of 23 patients received grafts perfused with HTK; another 23 patients transplanted with organs perfused with UW-MPS were matched based on recipient age and sodium model of end-stage liver disease score, donor age and sex, cold ischemia time, and perfusion time. Postoperative outcomes, perfusion parameters, and cost differences were assessed. Results: The HTK and UW-MPS cohorts demonstrated comparable perfusion dynamics and vascular resistance. While arterial pressure and flow were higher in the UW-MPS group, clinical outcomes—including early allograft dysfunction (47.8% each), ICU stay, and comprehensive complication index—were statistically similar. A trend toward fewer biliary complications (13.0% vs. 30.4%) and reduced hemodialysis requirement (17.4% vs. 30.4%) was observed in the HTK group. Use of HTK reduced perfusion-related costs by approximately EUR 560 per procedure. Conclusion: HTK is a viable alternative to UW-MPS during HOPE in OLT of DBD grafts, offering comparable short-term outcomes and relevant cost savings. Prospective studies are warranted to validate these findings and explore broader applications of single-solution perfusion strategies.

  • Open Access

    Dual hypothermic oxygenated machine perfusion of the liver reduces post-transplant biliary complications: a retrospective cohort study

    by David Pereyra, Jule Dingfelder, Moriz Riha, Sertac Kacar, Laurin Msc Rauter, Nikolaus Becker, Tina Saffarian Zadeh, Chiara Tortopis, Patrick Starlinger, Robin Ristl, et al.

    Background: Corroborating evidence for the use of hypothermic oxygenated machine perfusion (HOPE) prior to orthotopic liver transplantation (OLT) suggests a beneficial effect in regard to biliary complications. Here, the authors aim to evaluate whether perfusion via portal vein alone (sHOPE) or via additional perfusion of the hepatic artery (dHOPE) have diverging impact on outcomes after OLT when compared to the use of static cold storage (SCS). Methods: Consecutive patients undergoing OLT at the Medical University of Vienna (2018–2023) were retrospectively analyzed. Donor organs were procured using SCS, or subjected to end-ischemic sHOPE or dHOPE. The severity of biliary complications was classified according to the degree of therapeutic intervention (endoscopic retrograde cholangiopancreatography or surgical revision). Results: Two hundred forty-seven patients were included (69 SCS, 76 sHOPE, and 102 dHOPE). Hospitalization was shorter for patients after HOPE (median in days: SCS=25 vs HOPE=20, P=0.019). Biliary complications were less frequent in patients after HOPE (SCS=37.7% vs HOPE=22.5%, P=0.015). A significantly lower incidence of surgical revisions for biliary complications was observed in the HOPE cohort (24.6% vs 11.8%, P=0.012). When evaluating outcome according to HOPE-modality, a significant reduction in biliary complications (P=0.006) and surgical revisions (P=0.002) was only observed in dHOPE patients in comparison to SCS. Further, only dHOPE was significantly associated with a reduced need for surgical revision for biliary complications upon univariable and multivariable logistic regression (odds ratio=0.336, P=0.011). Conclusion: HOPE leads to a reduction of biliary complications and associated surgical revisions. This effect seems to be primarily associated with use of dHOPE, while both methods appear as feasible options for preconditioning of donor grafts prior to OLT.


  • Open Access

    Validation of mitochondrial FMN as a predictor for early allograft dysfunction and patient survival measured during hypothermic oxygenated perfusion

    by Jule Dingfelder, Dagmar Kollmann, Laurin Rauter, David Pereyra, Sertac Kacar, Anna M. Weijler, Tina Saffarian Zadeh, Chiara Tortopis, Gerd Silberhumer, Andreas Salat, et al.

    Hypothermic oxygenated machine perfusion (HOPE) preconditions liver grafts before transplantation. While beneficial effects on patient outcomes were demonstrated, biomarkers for viability assessment during HOPE are scarce and lack validation. This study aims to validate the predictive potential of perfusate flavin mononucleotide (FMN) during HOPE to enable the implementation of FMN-based assessment into clinical routine and to identify safe organ acceptance thresholds. FMN was measured in perfusate samples of 50 liver grafts at multiple time points. After transplantation, patients were followed up for development of early allograft dysfunction (EAD), transplantation, and 1-year survival. FMN concentrations were significantly higher for grafts that developed EAD at 5 and 60 minutes into HOPE (p = 0.008, p = 0.026). The strongest predictive potential of FMN for EAD was observed at 5 minutes of HOPE with an AUC of 0.744. Similarly, 5-minute FMN was predictive for 1-year mortality (p < 0.001), reaching a remarkable AUC of 0.890. Cutoffs for prediction of EAD (10.6 ng/mL) and early mortality (23.5 ng/mL) were determined and allowed risk stratification of grafts. Particularly, patients receiving low-risk grafts developed EAD in 9% of cases, while all patients survived the first postoperative year. In contrast, high-risk organs developed an incidence of EAD at 62%, accompanied by the necessity of retransplantation in 38% of cases. One-year mortality in the high-risk cohort was 62%. Evaluation of FMN as early as 5 minutes during HOPE allows for risk stratification of liver grafts. Low-risk grafts, according to FMN, display a negligible risk for patients. Yet, high-risk grafts are associated with increased risk for EAD, transplantation, and early mortality and should not be used for transplantation without further assessment.


  • Open Access

    A Multi-Centre Non-Interventional Study to Assess the Tolerability and Effectiveness of Extended-Release Tacrolimus (LCPT) in De Novo Liver Transplant Patients

    by Thomas Soliman, Georg Gyoeri, Andreas Salat, Vladimír Mejzlík, Gabriela Berlakovich

    Background: Available tacrolimus formulations exhibit substantial inter- and intra-individual variability in absorption and metabolism. The present non-interventional cohort study aimed to assess the tolerability and effectiveness of the once-daily tacrolimus formulation, LCPT, in hepatic allograft recipients in real life. Materials and methods: This study was conducted in Austria and the Czech Republic between July 2016 and August 2019. Patients aged ≥ 18 years old received LCPT per the approved label and local clinical routine. All the participants provided informed consent. Patients newly treated with tacrolimus (de novo) directly after transplantation were observed for six months. The relevant clinical variables were tacrolimus trough level (TL), total daily dose (TDD), number of dose adjustments, kidney and liver function, and tolerability. Results: Of the 70 analyzed patients, 72.9% were male and 85.7% were aged < 65 years old. The mean (SD) time to achieve tacrolimus target TL was 6.4 (4.6) days after 4.4 (4.0) dose adjustments; thereafter, TL remained stable throughout observation at approximately 8 ng/mL. The LCPT TDD at initiation was 8 mg and decreased by a median of 41.4% to 5 mg at 6 months. Liver function continuously improved, and kidney function remained stable. LCPT was well tolerated with 24 adverse events in eight patients (17 related to immunosuppression, mostly mild renal insufficiency, and hematological adverse events); two serious unrelated adverse events were reported (atrial flutter and liver dysfunction). Conclusions: TL was rapidly attained with few dose adaptations after LCPT initiation in de novo liver transplant patients. Liver function rapidly improved, whereas kidney function remained normal. LCPT was well-tolerated in this population.


  • Open Access

    313.16: Glycocalyx Damage Marker Syndecan-1 Correlates With Early Allograft Dysfunction During Hypothermic Liver Machine Perfusion

    by Laurin Rauter, Judith Schiefer, Pierre Raeven, Öhlinger Thomas, Marija Spasic, Effimia Pompouridou, Jule Dingfelder, Andreas Salat, Zoltan Mathé, Georg Györi, et al.

  • Open Access

    Prospective and single-blinded evaluation of the multi-cancer Carcimun-test

    by Andreas Salat, Wieland Voigt, Berthold von Und zu Zwerger

    Background: Timely diagnosis of cancer enables early treatment when interventions are most effective, but most cancer patients are being diagnosed at late stages after considerable tumor progression. Since current in vitro diagnostic tools identify distinct tumor derived proteins or mutations specific for certain types of tumors only, a more universal marker would foster early diagnosis. The Carcimun-test presented here detects specific conformational changes of plasma proteins in response to cancerogenesis by the optical extinction measurement thereby indicating general malignancy and acute inflammation. In this study, we assessed the feasibility and performance of the Carcimun-test in healthy volunteers and cancer patients. Methods: In this prospective, single-blinded study, plasma samples were obtained from 137 healthy donors and 170 patients with different histologically proven malignancies and subsequently assayed by Carcimun-testing. Participants with acute and chronic inflammation were excluded. An extinction threshold was defined to differentiate between healthy individuals and cancer patients. Participants were then followed-up to up to 5 years after Carcimun-testing to correlate test results with mortality and define false negative rate. Results: In the Carcimun-test, mean extinction values were significantly higher in cancer patients (n=170) than in healthy subjects (n=137; PConclusions: With the Carcimun-test, we present a clinically feasible tool to detect different tumor types with high specificity, sensitivity, and accuracy. Further studies are now planned to delineate the molecular mechanism of the Carcimun-test and to demonstrate its clinical relevance for the screening and early diagnosis of cancer.


  • Human Papilloma Virus (HPV)-associated proctologic diseases

    by A. Salat, A. Trost, J. Roka, F. Roka